Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 25557171
Huang HL, Chiang CH, Hung WC, Hou MF (2015) Targeting of TGF-β-activated protein kinase 1 inhibits chemokine (C-C motif) receptor 7 expression, tumor growth and metastasis in breast cancer. Oncotarget 6, 995-1007 25557171
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S176-p - IKKA (human)
Modsite: AKDVDQGsLCtsFVG SwissProt Entrez-Gene
Orthologous residues
IKKA (human): S176‑p, IKKA (mouse): S176‑p, IKKA (rat): S176‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1_inhibitor decrease

S181-p - IKKB (human)
Modsite: DQGsLCtsFVGTLQy SwissProt Entrez-Gene
Orthologous residues
IKKB (human): S181‑p, IKKB (mouse): S181‑p, IKKB (rat): S181‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1_inhibitor decrease

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1_inhibitor decrease

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1_inhibitor decrease

S73-p - Jun (human)
Modsite: VGLLkLAsPELERLI SwissProt Entrez-Gene
Orthologous residues
Jun (human): S73‑p, Jun (mouse): S73‑p, Jun (rat): S73‑p, Jun (cow): S73‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1_inhibitor decrease

S276-p - NFkB-p65 (human)
Modsite: sMQLRRPsDRELsEP SwissProt Entrez-Gene
Orthologous residues
NFkB‑p65 (human): S276‑p, NFkB‑p65 (mouse): S276‑p, NFkB‑p65 (rat): S276‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1_inhibitor decrease

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1_inhibitor decrease

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1_inhibitor decrease

T184-p - TAK1 (human)
Modsite: GtACDIQtHMtNNKG SwissProt Entrez-Gene
Orthologous residues
TAK1 (human): T184‑p, TAK1 (mouse): T184‑p, TAK1 iso3 (mouse): T184‑p, TAK1 (rat): T184‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1_inhibitor decrease

T187-p - TAK1 (human)
Modsite: CDIQtHMtNNKGsAA SwissProt Entrez-Gene
Orthologous residues
TAK1 (human): T187‑p, TAK1 (mouse): T187‑p, TAK1 iso3 (mouse): T187‑p, TAK1 (rat): T187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1_inhibitor decrease